We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 132

Teva Canada Innovation v. Attorney General of Canada

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 8 2013

The Patented Medicine Prices Review Board (the PMPRB) ordered Teva to pay the Crown approximately $2.4 million for selling its product at an

Definition of “innovative drug” does not include variations

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 23 2013

This is an appeal by Takeda of a decision of the Court, in which the Court upheld the decision of the Minister of Health to refuse to list Takeda’s

Intellectual property weekly abstracts bulletin

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 1 2013

The Court granted a Prohibition Order to AstraZeneca, preventing Ranbaxy from entering the market with a generic version of ompeprazole until the

Patent refused listing on the Patent Register

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 30 2012

The Federal Court dismissed a judicial review of a decision of the Minister of Health refusing to list a patent on the Patent Register

Court refuses to reconsider or vary its decision relating to redetermination

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • December 7 2010

The Patented Medicines Prices Review Board (PMPRB) made a decision that Teva’s product COPAXONE had been sold at an excessive price

Pleadings for disgorgement of profits and for an accounting of profits in s.8 damages not struck in Ontario court

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • August 1 2012

In this case, Apotex has claimed damages in Ontario Court pursuant to, inter alia, section 8 of the NOC Regulations. Lilly brought a motion to strike out parts of Apotex’ statement of claim

Finding of "fair expectation of success" leads to finding of obviousness

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 11 2013

Teva sent two Notices of Allegation, one in respect of 50mg tablets and the second in respect of 150, 200, 300 and 400mg tablets, which were addressed

Court grants motion to reopen trial and admit new evidence

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 27 2011

The Federal Court granted leave to reopen the trial and admit new evidence in a matter under reserve, in which no reasons or judgement have issued

Divisional patent application can be filed by applicant not named in original application

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • December 15 2010

This case is a judicial review of a decision of the Commissioner of Patents where recognition of a patent application as a divisional application was denied

BC pharmaceutical policy reforms

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 16 2010

Following the lead of Ontario, British Columbia has taken steps to further reform its provincial policy with respect to pharmaceuticals

Current Search

Suggested Facets

Author

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy